The SCD1 inhibitor aramchol interacts with regorafenib and metformin to kill tumor cells
Oncotarget · 2026
DOI: 10.18632/oncotarget.28861 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oncotarget, 2026. Verfasst von Michael R Booth und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298, USA. Hauptthemen laut MEDLINE: Metformin, Phenylurea Compounds, Pyridines. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA 23298, USA.
- Melanoma and Skin Cancer Program, Hillman Cancer Research Pavilion Laboratory, University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA.
Zitieren
APA
Booth, M. R., Booth, L., Roberts, J. L., Kirkwood, J. M., & Dent, P. (2026). The SCD1 inhibitor aramchol interacts with regorafenib and metformin to kill tumor cells. Oncotarget. https://doi.org/10.18632/oncotarget.28861
Vancouver
Booth MR, Booth L, Roberts JL, Kirkwood JM, Dent P. The SCD1 inhibitor aramchol interacts with regorafenib and metformin to kill tumor cells. Oncotarget. 2026. doi:10.18632/oncotarget.28861
BibTeX
@article{Booth2026,
author = {Booth, Michael R and Booth, Laurence and Roberts, Jane L and Kirkwood, John M and Dent, Paul},
title = {The SCD1 inhibitor aramchol interacts with regorafenib and metformin to kill tumor cells},
journal = {Oncotarget},
year = {2026},
doi = {10.18632/oncotarget.28861}
}
EUVIMED